FCM
BLTE

Farallon Capital Management’s Belite Bio BLTE Stock Holding History

Farallon Capital Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$207K Buy
+1,300
New +$219K ﹤0.01% 142

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Farallon Capital Management's BLTE Position: Q1 2026 in Review

Farallon Capital Management opened a new position in Belite Bio (BLTE) in Q1 2026: 1,300 shares worth $207K. The stake represents ﹤0.01% of the portfolio and ranks #142 among its holdings.

75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Farallon Capital Management held 1,300 shares of Belite Bio worth $207K as of Q1 2026.
  • Belite Bio was a new Farallon Capital Management position in Q1 2026.
  • Belite Bio made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #142 holding.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.